Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02542514
Recruitment Status : Active, not recruiting
First Posted : September 7, 2015
Last Update Posted : March 13, 2019
Sponsor:
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:
The study is an open label, prospective, multicenter, phase II study which aims to define ibrutinib efficacy in patients with relapsed or refractory primary central nervous lymphoma (PCNSL) or intraocular lymphoma (IOL) as measured by the disease control (DC) rate (complete response (CR) + uncertain complete response (Ru) + partial response (PR) stabilized disease (SD)) after 2 cycles of treatment according to International study group for PCNSL (IPCG) criteria.

Condition or disease Intervention/treatment Phase
Primary Central Nervous Lymphoma Intraocular Lymphoma Drug: Ibrutinib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma
Study Start Date : September 2015
Actual Primary Completion Date : August 2016
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Ibrutinib

Arm Intervention/treatment
Experimental: Ibrutinib
ibrutinib in monotherapy 28 days/cycles
Drug: Ibrutinib
p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)




Primary Outcome Measures :
  1. disease control rate (CR + CRu + PR +SD) [ Time Frame: 2 months ]
    Disease control (DC) rate (CR + CRu + PR + SD) after 2 cycles of treatment according to IPCG criteria.


Secondary Outcome Measures :
  1. Number of AE [ Time Frame: 12 months ]
    To evaluate tolerance and toxicity of ibrutinib.

  2. disease control [ Time Frame: 4, 6, 9 and 12 months ]
    according to IPCG criteria evaluated locally by investigators and the results of the MRI review (maximum of 6 MRI review per patient).

  3. overall response (OR) [ Time Frame: 4, 6, 9 and 12 months ]
    according to IPCG criteria evaluated locally by investigators and the results of the MRI review (maximum of 6 MRI review per patient).

  4. complete response (CR) rate [ Time Frame: 4, 6, 9 and 12 months ]
    according to IPCG criteria evaluated locally by investigators and the results of the MRI review (maximum of 6 MRI review per patient).

  5. overall survival (OS) [ Time Frame: 4, 6, 9 and 12 months ]
    according to IPCG criteria evaluated locally by investigators and the results of the MRI review (maximum of 6 MRI review per patient).

  6. time to progression [ Time Frame: 12 months ]
  7. progression-free survival (PFS) [ Time Frame: 12 months ]

Other Outcome Measures:
  1. concentration of ibrutinib in cerebrospinal fluid [ Time Frame: baseline and 2 months ]
    Pharmacokinetics of ibritunib in the cerebrospinal fluid.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed diagnosis of PCNSL or cytologically proven diagnosis of IOL or lymphomatous meningitis of B-cell type. In case of CNS lymphoma relapse or refractory PCNSL, cerebral biopsies are not required if imaging reveals typical images of PCNSL. In case of isolated IOL relapse, vitrectomy is not required if i) vitrectomy was part of the initial diagnosis workout, and ii) ocular examination and dosage of IL-10 in the anterior chamber of the eye performed at relapse or progression are highly in favour of IOL relapse (> 50 pg/ml in aqueous humor or 400 pg/ml in vitreous).
  2. Aged 18 years and older.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
  4. Life expectancy ≥ 3 months.
  5. No more than 4 lines of anti-cancer treatment received.
  6. Patients must have recovered within 28 days to a grade ≤ 1 from all toxicities related to prior treatments.
  7. Adequate Laboratory Parameters within 14 days:
  8. Measurable PCNSL as diagnosed on MRI
  9. Highly effective method of birth control during and after the study consistent. Men must agree to not donate sperm during and after the study. These restrictions apply for 1 year after the last dose of study drug.
  10. Women of childbearing potential must have a negative serum beta-hCG or urine pregnancy test at Screening.
  11. Sign of an informed consent document.The informed consent document can be signed by a person of confidence in case neurologic disorders related to the disease prevent the patient to sign himself.

Exclusion Criteria:

  1. Contraindication to any excipients of the drug.
  2. T-cell lymphoma.
  3. Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast), prior history of systemic lymphoma, unless the patient has been free of the disease for ≥ 3 years.
  4. Prior history of organ transplantation or other cause of severe immunodeficiency.
  5. Major surgery, within 4 weeks prior to the first dose of study drug.
  6. History of stroke or intracranial hemorrhage within 6 months prior to randomization. Patients with post-biopsies hemorrhagic sequela defined as a small hyperdense lesion < 3 mm on T2* sequence won't be excluded.
  7. Requires anticoagulation with warfarin or equivalent vitamin K antagonists or ongoing warfarin medication or other equivalent vitamin K antagonists.
  8. Any anti-platelet aggregant medication except acetyl salicylic acid ≤ 75 mg/day.
  9. Requires treatment with strong CYP3A4 inhibitors.
  10. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or Class 4 cardiac disease as defined by the New York Heart Association Functional Classification.
  11. Vaccinated with live, attenuated vaccines within 4 weeks prior to the first dose of study drug.
  12. Known history of HIV or active Hepatitis C Virus (HCV; RNA polymerase chain reaction [PCR]-positive) or active Hepatitis B Virus (HBs Ag positive or DNA PCR-positive) infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics.
  13. Any life-threatening illness, medical condition, or organ system dysfunction which could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
  14. Inability to swallow capsules.
  15. Pregnancy or lactation.
  16. Use of anti-cancer drug therapy within 21 days prior to the first dose of study drug.
  17. Previous treatment by BTK inhibitors and PI3K inhibitors.
  18. Known bleeding diathesis.
  19. Inclusion in another experimental anti-cancer drug therapy*.
  20. Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
  21. Patient under measure of legal protection.
  22. No social security affiliation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02542514


Locations
Layout table for location information
France
CHU d'ESTAING
Clermont Ferrand, France
CHU de Grenoble
Grenoble, France
CHRU de LILLE - Claude Huriez
Lille, France
Centre Léon Bérard
Lyon, France
CHU de la Pitié Salpêtrière
Paris, France
CHU de la Timone
Paris, France
CHU de Rennes
Rennes, France
Centre Henri Becquerel
Rouen, France
Hôpital René Huguenin Institut Curie
Saint-Cloud, France
CHU Brabois
Vandoeuvre les Nancy, France
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Investigators
Layout table for investigator information
Study Chair: Carole Soussain, MD Lymphoma Study Association

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier: NCT02542514     History of Changes
Other Study ID Numbers: iLOC
First Posted: September 7, 2015    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Keywords provided by The Lymphoma Academic Research Organisation:
PCNSL
IOL
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Intraocular Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Eye Neoplasms
Neoplasms by Site